03 November 2025
03 November 2025
Pfizer called Novo Nordisk’s last-minute bid to acquire Metsera “reckless and unprecedented”.
The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.
Xcellon Biologics will incorporate IntoCell’s OHPAS drug-linker system into its range of ADC development suites.
4D-150 delivers a sustained release of anti-vascular endothelial growth factor with one intravitreal injection.
Bayer and BI have reported broadly similar efficacy outcomes for sevabertinib and Hernexeos.
Sac-TMT will compete with two other TROP-2 targeted ADCs already approved: Gilead’s Trodelvy and AstraZeneca and Daiichi Sankyo’s Datroway.
Epioxa is a small molecule drug delivered as an eye drop that strengthens the cornea.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
